[go: up one dir, main page]

WO2008011178A3 - Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication - Google Patents

Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication Download PDF

Info

Publication number
WO2008011178A3
WO2008011178A3 PCT/US2007/016526 US2007016526W WO2008011178A3 WO 2008011178 A3 WO2008011178 A3 WO 2008011178A3 US 2007016526 W US2007016526 W US 2007016526W WO 2008011178 A3 WO2008011178 A3 WO 2008011178A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
intermittent claudication
omega
fatty acids
artery disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/016526
Other languages
French (fr)
Other versions
WO2008011178A2 (en
Inventor
Roelof M L Rongen
Robert A Ms Shalwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reliant Pharmaceuticals Inc
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Priority to EP07810680A priority Critical patent/EP2068861A4/en
Priority to JP2009521785A priority patent/JP2009544701A/en
Publication of WO2008011178A2 publication Critical patent/WO2008011178A2/en
Publication of WO2008011178A3 publication Critical patent/WO2008011178A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions comprising omega-3 fatty acids, where the compositions are useful for treating intermittent claudication, preventing its further progression, and treating underlying conditions such as PAD that cause IC symptoms, methods of making such compositions, methods of using the compositions to treat intermittent claudication, and methods of using the compositions to treat any of the various underlying conditions that cause intermittent claudication.
PCT/US2007/016526 2006-07-21 2007-07-23 Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication Ceased WO2008011178A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07810680A EP2068861A4 (en) 2006-07-21 2007-07-23 Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
JP2009521785A JP2009544701A (en) 2006-07-21 2007-07-23 Compositions containing omega-3 fatty acids and their use to treat peripheral arterial injury and intermittent claudication

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83213506P 2006-07-21 2006-07-21
US60/832,135 2006-07-21

Publications (2)

Publication Number Publication Date
WO2008011178A2 WO2008011178A2 (en) 2008-01-24
WO2008011178A3 true WO2008011178A3 (en) 2008-06-12

Family

ID=38957420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016526 Ceased WO2008011178A2 (en) 2006-07-21 2007-07-23 Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication

Country Status (3)

Country Link
EP (1) EP2068861A4 (en)
JP (1) JP2009544701A (en)
WO (1) WO2008011178A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
MX2011009503A (en) * 2009-03-09 2011-09-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof.
AU2010260129B2 (en) 2009-06-15 2014-05-29 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels
WO2016152054A1 (en) * 2015-03-26 2016-09-29 備前化成株式会社 Pain prevention and alleviation effects of ω3 fatty acid glyceride
BR112021002884A2 (en) * 2018-08-17 2021-05-11 Amarin Pharmaceuticals Ireland Limited methods to reduce the need for peripheral arterial revascularization in a statin-treated subject
PL4056176T3 (en) 2018-09-24 2024-08-26 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
KR20220122616A (en) 2019-11-12 2022-09-02 애머린 파마슈티칼스 아일랜드 리미티드 A method of reducing the risk of a cardiovascular event in a subject having atrial fibrillation and/or atrial flutter
EP4326244A4 (en) 2021-04-21 2025-03-19 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5698594A (en) * 1988-08-11 1997-12-16 Norsk Hydro A.S Treatment and prevention of risk factors for cardiovascular diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
EP1125914A1 (en) * 2000-02-14 2001-08-22 Nisshin Flour Milling Co., Ltd. Process for separating and purifying eicosapentaenoic acid or its ester
CN101098690A (en) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 Omega-3 fatty acids and dyslipidemia agents for lipid therapy
WO2006062748A2 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
EA200701913A1 (en) * 2005-03-08 2008-08-29 Релайэнт Фармасьютикалз, Инк. TREATMENT WITH STATIN, OMEGA-3 FATTY ACIDS AND THEIR COMBINED PRODUCT
WO2007011886A2 (en) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698594A (en) * 1988-08-11 1997-12-16 Norsk Hydro A.S Treatment and prevention of risk factors for cardiovascular diseases
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARRERO ET AL.: "Daily Supplementation with (n-3) PUFAs, Oleic Acid, Folic Acid, and Vitamins B-6 and E increase Pain-Free Walking Distance and Improves Risk Factors in Men with Peripheral Vascular Disease", JOURNAL OF NUTRITION, vol. 135, no. 6, June 2005 (2005-06-01), pages 1393 - 1399, XP008103124 *
See also references of EP2068861A4 *

Also Published As

Publication number Publication date
EP2068861A2 (en) 2009-06-17
WO2008011178A2 (en) 2008-01-24
JP2009544701A (en) 2009-12-17
EP2068861A4 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
WO2008011178A3 (en) Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
MX2008000178A (en) Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions.
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2007001851A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2010074588A3 (en) Pharmaceutical compounds
WO2006029183A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
PL2318035T3 (en) Methods and compositions for treating the symptoms of neurological disorders and mental health disorders
TW200712051A (en) Mixture of diisononyl esters of 1,2-cyclohexanedicarboxylic acid, process for their preparation and use of these mixtures
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2008129358A3 (en) Oil producing microbes and methods of modification thereof
WO2007117557A3 (en) Diaminopropanol renin inhibitors
WO2007109037A3 (en) Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
WO2009079451A3 (en) Compositions and methods of promoting wound healing
WO2008007227A3 (en) Method and compositions for relieving menopausal and perimenopausal symptoms
WO2007100765A3 (en) Lysozyme-modified probiotic components and uses thereof
IL185791A0 (en) Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease
EA200701995A1 (en) METHODS OF REDUCING CALCIFICATION
WO2007136857A3 (en) Hox compositions and methods
EP2801356A3 (en) DHA and EPA for the reduction of oxidative stress
UA88030C2 (en) Composition containing omega-3 fatty acids and omega-6 fatty acids for use in the treatment of dry eye syndrome
WO2010065861A3 (en) Inhibitors of bace 1 and methods for treating alzheimer's disease
WO2006081516A3 (en) USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
WO2006079068A3 (en) Compositions and methods for studying and treating inflammatory diseases and disorders
WO2007135518A3 (en) Use of choline-based preparations for the treatment of tinnitus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07810680

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009521785

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007810680

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU